XML 31 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies - Additional Information (Details) (USD $)
3 Months Ended
Mar. 31, 2015
Segment
Entity
Mar. 31, 2014
Dec. 31, 2014
Entity
Organization And Significant Accounting Policies [Line Items]      
Research and development commitments with third parties not incurred $ 6,828,000xon_ResearchAndDevelopmentCommitmentsNotYetIncurred   $ 2,183,000xon_ResearchAndDevelopmentCommitmentsNotYetIncurred
Maturity period of liquid investment 3 months    
Cash equivalent investments in highly liquid money market accounts 87,768,000us-gaap_MoneyMarketFundsAtCarryingValue   16,598,000us-gaap_MoneyMarketFundsAtCarryingValue
Number of collaborators over which the Company has significant influence 2xon_NumberOfCollaborators   2xon_NumberOfCollaborators
Fair value of financial assets measured at fair value on a recurring basis 387,188,000us-gaap_AssetsFairValueDisclosure   280,497,000us-gaap_AssetsFairValueDisclosure
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities 115,454,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 21,922,000us-gaap_FairValueOptionChangesInFairValueGainLoss1  
Variable interest entities, risk of loss 192,228,000us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount   0us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount
Percentage of recognized income tax positions 50.00%xon_IncomeTaxBenefitRecognitionCriteriaPercentageThreshold    
Number of segment 1us-gaap_NumberOfOperatingSegments    
Revenues 33,849,000us-gaap_Revenues 7,854,000us-gaap_Revenues  
Foreign Countries      
Organization And Significant Accounting Policies [Line Items]      
Long-lived assets 82,133,000us-gaap_NoncurrentAssets
/ us-gaap_StatementGeographicalAxis
= xon_ForeignCountriesMember
  17,100,000us-gaap_NoncurrentAssets
/ us-gaap_StatementGeographicalAxis
= xon_ForeignCountriesMember
Revenues 1,290,000us-gaap_Revenues
/ us-gaap_StatementGeographicalAxis
= xon_ForeignCountriesMember
0us-gaap_Revenues
/ us-gaap_StatementGeographicalAxis
= xon_ForeignCountriesMember
 
Equity Securities      
Organization And Significant Accounting Policies [Line Items]      
Fair value of financial assets measured at fair value on a recurring basis 294,922,000us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
  164,889,000us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
Oragenics, Inc.      
Organization And Significant Accounting Policies [Line Items]      
Company's ownership percentage 22.40%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_OragenicsMember
  24.40%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_OragenicsMember
Oragenics, Inc. | Equity Securities      
Organization And Significant Accounting Policies [Line Items]      
Fair value of financial assets measured at fair value on a recurring basis 8,128,000us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_OragenicsMember
  7,192,000us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_OragenicsMember
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities 936,000us-gaap_FairValueOptionChangesInFairValueGainLoss1
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_OragenicsMember
710,000us-gaap_FairValueOptionChangesInFairValueGainLoss1
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_OragenicsMember
 
ZIOPHARM Oncology, Inc.      
Organization And Significant Accounting Policies [Line Items]      
Company's ownership percentage 13.90%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_ZiopharmMember
  15.70%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_ZiopharmMember
ZIOPHARM Oncology, Inc. | Equity Securities      
Organization And Significant Accounting Policies [Line Items]      
Fair value of financial assets measured at fair value on a recurring basis 192,032,000us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_ZiopharmMember
  83,099,000us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_ZiopharmMember
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities $ 96,334,000us-gaap_FairValueOptionChangesInFairValueGainLoss1
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_ZiopharmMember
$ 3,934,000us-gaap_FairValueOptionChangesInFairValueGainLoss1
/ us-gaap_FairValueByAssetClassAxis
= us-gaap_EquitySecuritiesMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= xon_ZiopharmMember
 
Minimum      
Organization And Significant Accounting Policies [Line Items]      
Weighted Average Useful Life (Years) 2 years    
Minimum | Leasehold Improvements      
Organization And Significant Accounting Policies [Line Items]      
Property plant and equipment, useful life 1 year    
Maximum      
Organization And Significant Accounting Policies [Line Items]      
Weighted Average Useful Life (Years) 14 years    
Maximum | Leasehold Improvements      
Organization And Significant Accounting Policies [Line Items]      
Property plant and equipment, useful life 14 years